• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

COVID-19 vaccines and Multiple sclerosis

February 11, 2021
Recommend to a Colleague print
 

Includes the SARS-CoV-2 life cycle, vaccine targets, COVID-19 vaccines in use and in late-stage development, mRNA vaccine phase III data, and the Canadian Network of MS Clinics’ vaccine guidance.

19 slides

Download slide deck

TOPICS: COVID-19, Library, MS
Recommend to a Colleague

Related Posts

  • DMT prescribing in Canada – Part 2
    June 12, 2025
  • DMT prescribing in Canada – survey results
    June 6, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF
    June 2, 2025
  • Treatment discontinuation in MS: the DOT-MS trial
    May 5, 2025
  • CLINICAL CASES IN MS: A 24 Y.O. WOMAN WITH PARESTHESIAE AND NON-ENHANCING LESIONS
    April 25, 2025
Go back to home page

Browse by Topic

  • MS (415)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • McDonald criteria 2024: what changes can we expect? posted on January 30, 2024
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions